Mechanisms, biologic sequelae and clinical benefits of bortezomib-induced immunogenic cell death in multiple myeloma

Immunotherapy has achieved unprecedent long-term survival rates in solid tumors and has begun to transform myeloma (MM) treatment as well. Among strategies to enhance cancer cell immunogenicity, induction of immunogenic cell death (ICD) is particularly promising: the release of danger signals from dying cancer cells may, indeed, stimulate a specific anti-cancer immunity via T-cell priming by dendritic cells (DCs). Here, we sought to investigate the molecular basis and clinical relevance of bortezomib (BTZ)-induced ICD in MM.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 30, 2019 Category: Hematology Authors: Annamaria Gull à, Eugenio Morelli, Mehmet Samur, Teru Hideshima, Giada Bianchi, Mariateresa Fulciniti, Prabhal Rao, Srikanth Talluri, Yu-Tzu Tai, Dharminder Chauhan, Ruben Carrasco, Nikhil Munshi, Kenneth C. Anderson Source Type: research